Skip to main content
. 2023 Sep 19;15(18):4635. doi: 10.3390/cancers15184635

Figure 5.

Figure 5

LipoMP-LPS modifies immune cell populations and cytokine environment in tumors at the onset of tumor response. (A) Flow cytometry analyses of immune cell populations in the tumors of animal treated with high or low doses of LipoMP-LPS or PBS as control. Data are presented as mean ratio ± SEM of positive cells in each group. ns: not significant * p < 0.05, ** p < 0.005. High dose of LipoMP-LPS increases tumor infiltration by CD4 T-cells and increases the levels of M1 macrophages but not total macrophages into the tumors; (B) Cytokine expression profile evaluated by LegendplexTM in the same tumors. Data are mean ± SEM of the concentration (pg/mL) of each cytokine. High and low doses of LipoMP-LPS induce a moderate proinflammatory environment in tumors, characterized by a slight increase in levels of IL-6, IL-1b, IL-1a, IL-10 and GM-CSF and of the chemokines CCL2 and CXCL1 in tumors compared with control groups. ns: not significant * p < 0.05.